Vanderbilt-Ingram Cancer Center

VICC’s Levy to lead Rush University Cancer Center

Mia Levy, MD, PhD, director of Cancer Health Informatics and Strategy at Vanderbilt-Ingram Cancer Center (VICC) and Ingram Associate Professor of Cancer Research, has been named director of Rush University Cancer Center and Systems Vice President for Cancer Service at Rush University Medical Center in Chicago.

Park named to VICC breast cancer leadership position

trailer park

Study finds higher death rates in poor neighborhoods

Living in an economically disadvantaged neighborhood is likely to lead to death at an earlier age, especially among African-Americans, new research shows. The death rate is even more pronounced among disadvantaged individuals with unhealthy lifestyle habits.

Mathis strives to make her cancer journey meaningful

Amanda Mathis, chief financial officer of Bridgestone Americas, was just 35 when she first felt a lump in her right breast.

Vanderbilt-Ingram Cancer Center patients treated with new FDA-approved CAR-T therapy

Vanderbilt-Ingram Cancer Center has been selected as one of the few authorized treatment centers in the United States approved to administer the first FDA- approved chimeric antigen receptor T cell (CAR-T) therapy for treatment of adult patients with a specific type of lymphoma. VICC is the only cancer center in a seven-state region of the Southeast authorized to deliver the new immunotherapy.

red three darts arrows in the target center

Investigators match novel cancer mutations with potential therapies

Research led by Vanderbilt-Ingram Cancer Center (VICC) investigators may have solved a mystery about why a targeted therapy stops working in a small group of breast cancer patients.

1 20 21 22 23 24 28